Semaglutide vs Tirzepatide
A side-by-side research reference for Semaglutide and Tirzepatide — mechanism of action, catalogue data, and the key studies behind each compound.
| Comparison | ||
|---|---|---|
| Compound class | Peptides · Injectable vial | Peptides · Injectable vial |
| Mechanism of action | GLP-1 receptor agonist. Binds GLP-1 receptors in the hypothalamus and brainstem to modulate appetite signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. | Dual GLP-1 and GIP receptor agonist ("twincretin"). Activates both incretin receptors simultaneously — GIP amplifies insulin secretion and adipocyte lipolysis while GLP-1 modulates appetite and gastric emptying. |
| Reference concentration | 10mg | 30mg |
| Research form | Injectable vial | Injectable vial |
Key studies on Semaglutide
Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM STEP Study)Semaglutide reduces cardiovascular and metabolic risk factors in obesity (SELECT Trial)GLP-1 receptor agonist semaglutide and body weight regulation mechanismsSemaglutide improves glycemic control and reduces cardiovascular events in Type 2 Diabetes
Key studies on Tirzepatide
Tirzepatide versus Semaglutide for Type 2 Diabetes Management (NEJM SURPASS Study)Tirzepatide dual GLP-1/GIP agonist for chronic weight management (SURMOUNT-1 Trial)Tirzepatide demonstrates superior weight loss compared to semaglutide monotherapyGLP-1/GIP receptor dual agonism: mechanism and metabolic benefits of tirzepatide
More comparisons
Research Use Only
All compounds referenced on this page are sold for in vitro laboratory research use only. Not for human consumption, medical use, or self-administration. Not evaluated by the FDA. This page is for research and informational purposes only.